Rapid Microbiology test is the process of examining transmission modes, infection and growth mechanism and features of pathogens. Rapid microbiology test enables rapid diagnosis of infection with accuracy, which helps patient for implementation of proper infection control measures and early treatment. Such tests provide faster test results as compared to the traditional method testing and also help in getting the quantitative and qualitative results. Such tests provide numerous testing methodologies which include polymerase chain reaction (PCR) technologies and nucleic acid hybridization. These tests have the provision of giving accurate outcomes and are highly sensitive in nature.
U.S. Food and Drug Administration (FDA) started numerous initiatives that are adopted by several industries to facilitate rapid microbiology methods. The first program was Process Analytical Technology initiative (PAT). This program was started to reassure that new smart technologies are being used by industries and to measure the effectiveness of manufacturing process. This program was aimed at quality assurance, faster results, and increased control.
U.S. Food and Drug Administration (FDA) started another program initiative for the 21st Century; the Pharmaceutical cGMPs that have positively impacted rapid microbiology testing market. There are numerous advantages offered by the introduction of this initiative in the area of rapid microbiology. Under this program, there will be a selection of specially trained and skilled pharmaceutical inspectorate. These inspectorates will be provided specific training related to the investigation of pharmaceutical industrial facilities and experience in rapid microbiology which reassure that rapid microbiology methods are assessed in correct systematic manner.
Major drivers for rapid microbiology test markets are the increasing need for fast and easy diagnosis technological advancement in the healthcare industry, improved patients satisfaction due to the removal of usage of drugs. In addition, augmented prospective of bioterrorism tests and the threat of communication of AIDS are the significant factors that have led the continuous expansion of the market. However, advancement in molecular diagnostic technologies might impede the growth of the rapid microbiology test market.
Geographically, the market can be segmented into North America, Europe, Asia- Pacific and LAMEA. North America is expected to be dominant in the rapid microbiology tests market due to several healthcare focused companies giving a wide range of treatments and products and followed by Europe. The Asia Pacific and Latin America market is driven by factors such as the rise in the number of laboratories in emerging countries, enhancement of technology of the existing ones and innovation of new products. Furthermore, the upsurge in research and development and investment in innovation of new technology for the rapid microbiology testing methods are expected to boost the growth of rapid microbiology market.
Major players running in the market are Quidel Corporation, Thermo-Fisher Scientific Inc., Hoffmann-La Roche Ltd., Sysmex Corporation, Siemens Healthcare Diagnostics Inc., Gen-Probe Inc., Becton Dickinson, Abbott Laboratories and Bio-Rad Laboratories.
In 30 May 2018, Siemens Healthineers, world’s leading company of healthcare and ScreenPoint Medical, leading company in machine learning applications, have come together for the strategic partnership to design and innovate artificial intelligence (AI) based applications for breast imaging. This collaboration also involves the purchase of minority stake in ScreenPoint Medical by Siemens Healthineers. The partnership has been initialized to utilize the expertise of both the companies and develop advanced clinical applications for breast cancer diagnosis and imaging.
In 31 May 2018, Abbott Laboratories, a world leading company in delivering healthcare services announced the launch of its Afinion™ 2 analyzer that is the newest generation of the Afinion test system. This test helps in diabetes care by empowering patients with insightful data and important information about their health. This test is a multi-assay platform that simplifies the process of accurate measurements of hemoglobin A1C (HbA1c) and delivery of actionable. This test gives faster result and guide physician to take the decision so that patients can be assured by a single visit.
• Technology Type
o Nucleic Acid Based Test
o Antibody Based Test
o Biochemical Test
o Enzymatic Test
o Flow Cytometry Methods
• End User
o Food and Beverages
o Personal Care
• Regions Covered:
o North America (U.S and Canada)
o Europe (Germany, France, Italy and Rest of Europe)
o Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
o LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)